Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.49 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.49 |
| ▸ | MAPT | P10636 | 3/20 | 0.49 |
| ▸ | RAD51 | Q06609 | 1/20 | 0.47 |
| ▸ | F2 | P00734 | 1/20 | 0.46 |
| ▸ | F12 | P00748 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.45 |
| ▸ | MEN1 | O00255 | 2/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.45 |
| ▸ | THRB | P10828 | 1/20 | 0.45 |
| ▸ | GFER | P55789 | 1/20 | 0.45 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.45 |
| ▸ | GAA | P10253 | 2/20 | 0.45 |
| ▸ | HTT | P42858 | 1/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | TP53 | P04637 | 1/20 | 0.44 |
| ▸ | CCNE1 | P24864 | 1/20 | 0.43 |
| ▸ | CDK2 | P24941 | 1/20 | 0.43 |
| ▸ | CDK5 | Q00535 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28473291 | 0.80 | ALDH1A1 (0.49) | ALDH1A1CYP1A2MAPTRAD51F2 | |
| SCHEMBL3421583 | 0.78 | GAA (0.60) | ALDH1A1KMT2AMEN1THRBGAA | |
| SCHEMBL7244914 | 0.77 | ALDH1A1 (0.56) | ALDH1A1CYP1A2MAPTRAD51F2 | |
| SCHEMBL29777624 | 0.76 | POLB (0.56) | ALDH1A1CYP1A2MAPTHTTSMN1; SMN2 | |
| SCHEMBL3064600 | 0.76 | — | — | |
| SCHEMBL696662 | 0.76 | KMT2A (0.58) | CYP1A2F2F12KMT2AMEN1 | |
| SCHEMBL896838 | 0.75 | CCNA2 (0.62) | ALDH1A1CYP1A2MAPTF2F12 | |
| SCHEMBL1011540 | 0.75 | RAB9A (0.59) | ALDH1A1MAPTF2F12KMT2A | |
| SCHEMBL13038790 | 0.75 | SMN1; SMN2 (0.59) | ALDH1A1MAPTKMT2AMEN1HTT | |
| SCHEMBL31286005 | 0.75 | RAB9A (0.59) | ALDH1A1MAPTF2F12KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12630562-B2 | Piperidylurea compounds and methods of use thereof | ARCUS BIOSCIENCES, INC. (US) | 2026-05-19 | — | — | US | disclosed |
| US-20260042777-A1 | PIPERIDYLUREA COMPOUNDS AND METHODS OF USE THEREOF | ARCUS BIOSCIENCES, INC. (US) | 2026-02-12 | — | — | US | disclosed |
| CN-108329246-B | Pyrrolidinyl urea and pyrrolidinyl thiourea compounds as TRKA kinase inhibitors | 阵列生物制药公司 | 2021-02-26 | — | — | CN | disclosed |
| CN-104903310-B | Bicyclic urea, thiourea, guanidine and cyanoguanidine compounds useful for the treatment of pain | 阵列生物制药公司 | 2018-08-14 | — | — | CN | disclosed |
| CN-108329246-A | Pyrrolidinyl urea and pyrrolidinyl thiourea compound as TRKA kinase inhibitors | 阵列生物制药公司 | 2018-07-27 | — | — | CN | disclosed |
| CN-105130967-B | Pyrrolidinyl urea and pyrrolidinyl thiourea compound as TRKA kinase inhibitors | 阵列生物制药公司 | 2018-04-17 | — | — | CN | disclosed |
| CN-105130967-A | Pyrrolidinyl urea and pyrrolidinyl thiourea compounds as trka kinase inhibitors | ARRAY BIOPHARMA INC | 2015-12-09 | — | — | CN | disclosed |
| CN-104903310-A | Bicyclic urea, thiourea, guanidine and cyanoguanidine compounds useful for the treatment of pain | ARRAY BIOPHARMA INC | 2015-09-09 | — | — | CN | disclosed |
| CN-103649076-B | Pyrrolidinyl urea and pyrrolidinyl thiourea compounds as TRKA kinase inhibitors | ARRAY BIOPHARMA INC. (US) | 2015-09-09 | — | — | CN | disclosed |
| CN-103649076-A | Pyrrolidinyl urea and pyrrolidinyl thiourea compounds as trka kinase inhibitors | ARRAY BIOPHARMA INC | 2014-03-19 | — | — | CN | disclosed |
| US-20120083476-A1 | HETEROARYL-SUBSTITUTED SPIROCYCLIC DIAMINE UREA MODULATORS OF FATTY ACID AMIDE HYDROLASE | JANSSEN PHARMACEUTICA NV (BE) | 2012-04-05 | — | — | US | disclosed |
| US-20120083476-A1 | HETEROARYL-SUBSTITUTED SPIROCYCLIC DIAMINE UREA MODULATORS OF FATTY ACID AMIDE HYDROLASE | JANSSEN PHARMACEUTICA NV (BE) | 2012-04-05 | — | — | US | disclosed |
| US-20120083476-A1 | HETEROARYL-SUBSTITUTED SPIROCYCLIC DIAMINE UREA MODULATORS OF FATTY ACID AMIDE HYDROLASE | JANSSEN PHARMACEUTICA NV (BE) | 2012-04-05 | — | — | US | disclosed |
| WO-2010141817-A1 | HETEROARYL-SUBSTITUTED SPIROCYCLIC DIAMINE UREA MODULATORS OF FATTY ACID AMIDE HYDROLASE | JANSSEN PHARMACEUTICA NV (BE) | 2010-12-09 | — | — | WO | disclosed |
| WO-2010141817-A1 | HETEROARYL-SUBSTITUTED SPIROCYCLIC DIAMINE UREA MODULATORS OF FATTY ACID AMIDE HYDROLASE | JANSSEN PHARMACEUTICA NV (BE) | 2010-12-09 | — | — | WO | disclosed |
| EP-0083613-A1 | N-PHENYLPYRAZOLE DERIVATIVES USEFUL AS HERBICIDES. | MAY & BAKER LTD (GB) | 1983-07-20 | — | — | EP | disclosed |
| WO-1983000332-A1 | N-PHENYLPYRAZOLE DERIVATIVES USEFUL AS HERBICIDES | MAY & BAKER LTD (GB) | 1983-02-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12630562-B2 | Piperidylurea compounds and methods of use thereof | CLIC1, HCCS, CNR1 | ALDH1A1 1002/4885CYP1A2 259/4885MAPT 4783/4885 |
| US-20120083476-A1 | HETEROARYL-SUBSTITUTED SPIROCYCLIC DIAMINE UREA MODULATORS OF FATTY ACID AMIDE HYDROLASE | FAAH, FAAH2, DBH | ALDH1A1 709/4885CYP1A2 1649/4885MAPT 1489/4885 |
| US-20260042777-A1 | PIPERIDYLUREA COMPOUNDS AND METHODS OF USE THEREOF | CBR1, CLIC1, RER1 | ALDH1A1 1208/4885CYP1A2 642/4885MAPT 4762/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.